Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H28N2O5.ClH |
| Molecular Weight | 412.908 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC(=O)N(C1=CC=CC=C1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC
InChI
InChIKey=WFBMIPUMYUHANP-UHFFFAOYSA-N
InChI=1S/C20H28N2O5.ClH/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2;/h5-9H,4,10-15H2,1-3H3;1H
| Molecular Formula | C20H28N2O5 |
| Molecular Weight | 376.4467 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The
µ-opioid activity of ULTIVA is antagonized by opioid antagonists such as naloxone. ULTIVA is indicated for IV administration:
1. As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.
2. For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.
3. As an analgesic component of monitored anesthesia care in adult patients.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ULTIVA Approved UseULTIVA is indicated for IV administration: 1.As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. 2.For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. 3.As an analgesic component of monitored anesthesia care in adult patients. Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
194 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
745 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8080 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30% |
0.5 μg/kg/min 1 times / day other, intravenous dose: 0.5 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Magnesium as part of balanced general anaesthesia with propofol, remifentanil and mivacurium: a double-blind, randomized prospective study in 50 patients. | 2001-11 |
|
| The bispectral index during an anaphylactic circulatory arrest. | 2001-10 |
|
| Effect of age on recovery from remifentanil anaesthesia. | 2001-10 |
|
| Goal oriented general anesthesia for Cesarean section in a parturient with a large intracranial epidermoid cyst. | 2001-10 |
|
| Threshold-level repetitive transcranial electrical stimulation for intraoperative monitoring of central motor conduction. | 2001-10 |
|
| A comparison of fentanyl, sufentanil, and remifentanil for fast-track cardiac anesthesia. | 2001-10 |
|
| Effects of the opioid remifentanil on olfactory function in healthy volunteers. | 2001-09-28 |
|
| Effects of cerebrospinal fluid loss and epidural blood patch on cerebral blood flow in swine. | 2001-09-19 |
|
| A comparison of propofol and remifentanil for sedation and limitation of movement during periretrobulbar block. | 2001-09 |
|
| Hemodynamics and emergence profile of remifentanil versus fentanyl prospectively compared in a large population of surgical patients. | 2001-09 |
|
| Does functional ability in the postoperative period differ between remifentanil- and fentanyl-based anesthesia? | 2001-09 |
|
| Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison between female and male patients. | 2001-09 |
|
| Effects of remifentanil/propofol in comparison with isoflurane on dynamic cerebrovascular autoregulation in humans. | 2001-09 |
|
| Remifentanil and fentanyl during anaesthesia for major abdominal and gynaecological surgery. An open, comparative study of safety and efficacy. | 2001-09 |
|
| Potential hazard with syringe infusion pump. | 2001-09 |
|
| Facilitation of laryngeal mask airway insertion: effects of remifentanil administered before induction with target-controlled propofol infusion. | 2001-09 |
|
| The in vitro effects of remifentanil, sufentanil, fentanyl, and alfentanil on isolated human right atria. | 2001-09 |
|
| Quantitative EEG changes associated with loss and return of consciousness in healthy adult volunteers anaesthetized with propofol or sevoflurane. | 2001-09 |
|
| Patient-controlled analgesia for labour using remifentanil: a feasibility study. | 2001-09 |
|
| Sevoflurane with remifentanil allows rapid tracheal intubation without neuromuscular blocking agents. | 2001-08-10 |
|
| [Esterase-metabolized remifentanil hydrochloride opioid (Ultiva-TM), a new step towards the solution of the problem of regulation of analgetic components of general anesthesia]. | 2001-08-10 |
|
| Influence of hypotensive and normotensive anesthesia on platelet aggregability and hemostatic markers in orthognathic surgery. | 2001-08-01 |
|
| Remifentanil. | 2001-08 |
|
| [Mastocytosis: general anesthesia with remifentanil and sevoflurane]. | 2001-08 |
|
| Target-controlled infusion or manually controlled infusion of propofol in high-risk patients with severely reduced left ventricular function. | 2001-08 |
|
| The use of remifentanil to facilitate the insertion of the laryngeal mask airway. | 2001-08 |
|
| Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy. | 2001-08 |
|
| [Remifentanil for palliative abdominal surgery in a patient with myasthenia gravis]. | 2001-07-12 |
|
| Opioid chronopharmacology. | 2001-07 |
|
| Anaesthetic management of a child with a positive family history of malignant hyperthermia for posterior fossa surgery in the sitting position. | 2001-07 |
|
| Esmolol is not an alternative to remifentanil for fast-track outpatient gynecologic laparoscopic surgery. | 2001-07 |
|
| Monitored anesthesia care using remifentanil and propofol for awake craniotomy. | 2001-07 |
|
| Postoperative reading speed does not indicate implicit memory in elderly cardiac patients after propofol and remifentanyl anaesthesia. | 2001-07 |
|
| Outpatient laparoscopic adrenalectomy in patients with Conn's syndrome. | 2001-06 |
|
| Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. | 2001-06 |
|
| Bispectral index monitoring in sevoflurane and remifentanil anesthesia. Analysis of drugs management and immediate recovery. | 2001-06 |
|
| Safety and efficacy of remifentanil infusion in craniosynostosis repair in infants. | 2001-06 |
|
| Effect of tracheal intubation or laryngeal mask airway insertion on intraocular pressure using balanced anesthesia with sevoflurane and remifentanil. | 2001-06 |
|
| Clonidine decreases propofol requirements during anaesthesia: effect on bispectral index. | 2001-05 |
|
| [Anesthesia in extreme obesity]. | 2001-05 |
|
| [Droperidol and dimenhydrinate alone or in combination for prevention of postoperative nausea and vomiting]. | 2001-05 |
|
| [General anesthesia with remifentanil in two cases of emergency cesarean section]. | 2001-05 |
|
| Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia. | 2001-04 |
|
| Recovery from propofol anaesthesia supplemented with remifentanil. | 2001-03 |
|
| Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients. | 2001-01 |
|
| Recovery and neurological examination after remifentanil-desflurane or fentanyl-desflurane anaesthesia for carotid artery surgery. | 2001-01 |
|
| Use of remifentanil in a patient with peripartum cardiomyopathy requiring Caesarean section. | 2001-01 |
|
| Target controlled infusion of remifentanil and propofol for cesarean section in a patient with multivalvular disease and severe pulmonary hypertension. | 2001 |
|
| Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery. | 2001 |
|
| [Total intravenous anesthesia using remifentanil and propofol with midazolam co-induction in laparoscopic surgery of the gallbladder]. | 2001 |
Patents
Sample Use Guides
Usual Adult Dose for Anesthesia
Induction of Anesthesia: Continuous IV infusion: 0.5 to 1 mcg/kg/min. If endotracheal intubation is to occur in less than 8 minutes, an initial dose of 1 mcg/kg may be administered over 30 to 60 seconds.
Maintenance of Anesthesia: With Nitrous Oxide, 0.4 mg/kg/min by continuous IV infusion.
Infusion dose range: 0.1 to 2 mcg/kg/min.
Supplemental IV bolus: 1 mcg/kg every 2 to 5 minutes.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:19 GMT 2025
by
admin
on
Mon Mar 31 17:59:19 GMT 2025
|
| Record UNII |
5V444H5WIC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5V444H5WIC
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL1005
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
m9521
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
5V444H5WIC
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
SUB04215MIG
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
236540
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID50157614
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
C47702
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
60814
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
32091
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
100000090469
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
132539-07-2
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
DBSALT001450
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
19291
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY | |||
|
DD-66
Created by
admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
||
|
|
IMPURITY -> PARENT |
|
![Structure of Methyl 3-[4-cyano-4-[phenyl(propanoyl)amino]piperidin-1-yl]propanoate](/img/e063a84e-53f4-48c9-a3b3-a6a6c68d8ea1.svg "Structure of Methyl 3-[4-cyano-4-[phenyl(propanoyl)amino]piperidin-1-yl]propanoate")
![Structure of Methyl 4-[butanoyl(phenyl)amino]-1-(3-methoxy-3-oxopropyl)piperidine-4-carboxylate](/img/afa2f945-84e7-4061-9412-1b562a9a6513.svg "Structure of Methyl 4-[butanoyl(phenyl)amino]-1-(3-methoxy-3-oxopropyl)piperidine-4-carboxylate")
![Structure of Methyl 1-(3-methoxy-3-oxopropyl)-4-[(2-methyl-3-oxopentanoyl)(phenyl)amino]piperidine-4-carboxylate](/img/b1857019-ab36-480e-ba23-7fba8a229e5e.svg "Structure of Methyl 1-(3-methoxy-3-oxopropyl)-4-[(2-methyl-3-oxopentanoyl)(phenyl)amino]piperidine-4-carboxylate")
![Structure of Methyl 3-[4-cyano-4-(phenylamino)piperidin-1-yl]propanoate](/img/cc0886cc-9477-4e40-abb0-f6dc2b5d0dd0.svg "Structure of Methyl 3-[4-cyano-4-(phenylamino)piperidin-1-yl]propanoate")
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|